Back to Trials
NCT04078230NARecruiting

Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Start Date

1/1/2020

Completion Date

12/31/2027

Summary

Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma. The eighth edition of the AJCC guidelines recommends at least 6 lymph nodes to be used for staging. The American Hepatobiliary and Pancreatic Association also recommends the removal of hilar lymph nodes as part of the radical surgery for intrahepatic cholangiocarcinoma. However, some scholars have found that patients with regional lymph nodes have similar survival rates. This contradictory result has prompted more scholars to conduct clinical research to explore the necessity and standardization of lymph node dissection in intrahepatic cholangiocarcinoma.

Detailed Description

Expanding lymph node dissection can theoretically obtain more lymph node dissection. Obtaining enough lymph nodes can improve the accuracy of AJCC staging and accurately determine prognosis. However, it is unclear whether it will improve the prognosis of patients with lymph node dissection. According to literature reports and related studies, expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and left lymphoma expanded lymph node dissection includedstations 12, 1, 3, 7, and 8. In summary, standardize the extent of lymph node dissection in intrahepatic cholangiocarcinoma, and obtain enough lymph node dissection under the premise of controlling the complication rate, which is helpful for accurate TNM staging, accurate judgment of prognosis and improvement of survival time. Improve prognosis.

Eligibility Criteria

Age Range: 18 years to 80 years

Inclusion Criteria: * Patients \>18 years of age and ≤80 years of age; * Preoperative imaging and laboratory examination for intrahepatic cholangiocarcinoma, intraoperative frozen and postoperative pathology confirmed as intrahepatic cholangiocarcinoma; preoperative imaging assessment is resectable; * No obvious lymph node metastasis in preoperative imaging; or negative intraoperative lymph node biopsy * Liver function Child-Turcotte-Pugh score A-B grade; * Residual liver volume \>30%; can tolerate radical hepatectomy * The patient has autonomy, understands and voluntarily signs the written informed consent and is able to complete the follow-up plan; * Sign the written informed consent form prior to the test screening. Exclusion Criteria: * The patient has obvious heart, lung, brain and kidney dysfunction that affects the treatment of intrahepatic cholangiocarcinoma; * The patient has a history of other malignant tumors; * Liver function Child-Turcotte-Pugh score C; * The investigator determined that it was not suitable for the study.

Interventions

PROCEDURE

Extend LymphAdenectomy

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Intrahepatic Cholangiocarcinoma

Locations

The Johns Hopkins Hospital

Baltimore, Maryland 10017

United States

China-Japan Friendship Hospital

Beijing, Beijing Municipality

China

Chinese PLA General Hospital

Beijing, Beijing Municipality

China

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Guangzhou, Guangdong

China

Hunan Provincial People's Hospital

Changsha, Hunan

China

The Affiliated Hospital of Inner Mongolia Medical University

Hohhot, Inner Mongolia

China

Renji Hospital Affiliated to Shanghai Jiao Tong University

Shanghai, Shanghai Municipality

China

Xinhua Hospital Affiliated to Shanghai Jiao Tong University

Shanghai, Shanghai Municipality

China

Zhong Shan Hospital Fudan University

Shanghai, Shanghai Municipality

China

The First Affiliated Hospital of Xi 'an Jiaotong University

Xi’an, Shanxi

China

West China Hospital Sichuan University

Chengdu, Sichuan

China

The Second Affiliated Hospital Zhejiang University School of Medicine

Hanzhou, Zhejiang 310009

China

Zhejiang cancer hospital

Hanzhou, Zhejiang

China